REFERENCES

1. Asherson RA, Cervera R, de Groot PG, *et al.* Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. *Lupus*. 2003;**12**(7):530–4.
2. Pineton de Chambrun M, Larcher R, Pène F, *et al.* In-Hospital Mortality-Associated Factors in Patients With Thrombotic Antiphospholipid Syndrome Requiring ICU Admission. *Chest*. 2020;**157**(5):1158–66.
3. Pineton de Chambrun M, Larcher R, Pène F, *et al.* CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. *J Autoimmun*. 2019;**103**:102292.
4. Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. *J Autoimmun*. 2018;**92**:1–11.
5. Legault K, Schunemann H, Hillis C, *et al.* McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. *J Thromb Haemost*. 2018.

30

REFRACTORY CUTANEOUS LUPUS: USE OF THALIDOMIDE OR LENALIDOMIDE FOR REFRACTORY LUPUS SKIN DISEASE

Francois Chasset. Sorbonne University, Paris, France

10.1136/lupus-2021-la.30

Cutaneous lupus erythematosus (CLE) may cause extensive skin damage leading to aesthetic prejudice and poor quality of life. Antimalarial agents are recommended as first-line systemic therapy for CLE patients with moderate-to-severe skin lesions. In case of failure of antimalarial agents, a European expert consensus for CLE treatment and EULAR recommendation for systemic lupus erythematosus (SLE) recommend adding quinine, methotrexate, retinoids, dapsone or mycophenolate mofetil.¹ However, the overall efficacy of these second-line treatments is approximately 50% depending on CLE subtypes and may be associated with potential toxicity. Thalidomide (α-N-phthalimidoglutarimide) is currently recommended as a ‘rescue’ therapy in patients with severe and refractory CLE treatment. However, in France, a ‘Temporary Recommendations for Use’ has been granted for thalidomide in CLE after failure of antimalarials as second-line agent.^{1–2} Moreover, in a systematic literature review including 21 observational studies and 548 patients the pooled rate of response to thalidomide 50–100mg/day was 90% (95% CI, 85–94), with similar response rates between CLE subtypes.³ The clinical benefits need to be balanced against potential adverse events with a pooled rate of thalidomide withdrawal related to adverse events of 24% (95% CI 14–35) including high teratogenicity, peripheral neuropathy 16% (95% CI 9–25), thromboembolic events in 2% (95% CI 1–3). Moreover, the efficacy of thalidomide is only suppressive with a rate of relapse of 71% (95% CI 65–77) after thalidomide withdrawal which supports the use of a minimal maintenance dose.³ In case of failure of thalidomide, lenalidomide 5 mg/day a 4-amino-glutamyl analogue of thalidomide has shown promising results with partial response of 88% in a retrospective study of 40 patients.⁴ Importantly, no cases of new or worsening peripheral thalidomide-induced neuropathy was reported with lenalidomide.⁴ A case of progression to SLE with renal involvement was reported in a patient with isolated CLE after starting lenalidomide.⁵ Recent data did not confirm this finding but suggested that lenalidomide has little or no effect on global SLE activity.

Learning Objectives

- Describe the therapeutic strategy in CLE
- Explain when to prescribe thalidomide and lenalidomide
- Discuss the safety profile of thalidomide and lenalidomide

REFERENCES

1. Fanouriakis A, Kostopoulou M, Alunno A, *et al.* 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;**78**(6):736–45.
2. Kuhn A, Aberer E, Bata-Csörgő Z, *et al.* S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). *J Eur Acad Dermatol Venereol*. 2017;**31**(3):389–404.
3. Chasset F, Tounsi T, Cesbron E, *et al.* Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2018;**78**(2):342–50.e4.
4. Aitmehdi R, Arnaud L, Francès C, *et al.* Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: a multicenter retrospective observational study of 40 patients. *J Am Acad Dermatol*. 2020.
5. Braunstein I, Goodman NG, Rosenbach M, *et al.* Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. *J Am Acad Dermatol*. 2012;**66**(4):571–82.

31

OSTEONECROSIS: PREVENTION AND TREATMENT

Bernardo Pons-Estel. Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina

10.1136/lupus-2021-la.31

Osteonecrosis (ON) is a well-known component of damage accrual in patients with systemic lupus erythematosus (SLE), it frequently causes disability and considerably affects patients’ quality of life.

The increased incidence of ON in SLE patients as compared to the general population, patients with other autoimmune diseases, or diseases requiring high doses of corticosteroids (CS) suggest that the disease itself and/or the underlying genetic background of the patients might dictate the susceptibility in its occurrence.^{1–5} Several modifiable risk factors have been associated with an increased risk of ON, such as alcohol intake, cigarette smoking, high triglyceride levels, and heavy physical work. The use of CS has been recognized as a major risk factor for the development of ON. The average daily dose of CS, its highest dose, and the total cumulative CS dose, as well as the use of pulse therapy, and the presence of Cushingoid appearance have all been associated with ON. The prevalence of ON in patients with SLE ranges between 5–15% but it may be as high as 40% when patients with silent patterns are included. The clinical presentation of ON is variable, being related to the size and location of the affected bone(s). The hip and knee are the most frequently affected joints followed by ankle and shoulder. Multifocal ON has been reported in up to half of patients with SLE.

The early diagnosis of ON is challenging because it frequently occurs silently; there is often a time lag between the development of ON and the onset of symptoms. Preventing ON involves controlling modifiable risk factors. Corticosteroids, if needed, should be prescribed at the lowest possible dose and for the shortest period of time, regardless of patient’s disease manifestations. Anticoagulant therapy, and statins/lipid-lowering drugs, may reduce the incidence of CS-induced ON.

The therapeutic approach depends largely on the joint involved and the extent of the injury. Immobilization has a role for small lesions that will spontaneously heal. Various medications have been used anecdotally with some benefit, including lipid-lowering drugs, anticoagulants, vasodilators, and bisphosphonates. Stem cell treatment of femoral head ON has